Ultragenyx gains FDA approval for Fayuvi, a Sanfilippo syndrome A therapy, easing impact of recent Angelman setback

Ultragenyx announced that the FDA has approved its drug Fayuvi for treating Sanfilippo syndrome type A, a rare neurodegenerative condition affecting children. The approval marks the company's first gene‑therapy clearance and adds to its portfolio of treatments for ultra‑rare diseases.

The clearance follows an earlier regulatory nod in August for another gene‑therapy candidate, helping the firm demonstrate continued progress despite recent setbacks. These approvals come at a critical time as the company seeks to balance its pipeline development.

In contrast, Ultragenyx recently reported a Phase 3 failure in an Angelman syndrome program, prompting the CEO to discuss cost‑structure adjustments. The new approvals are expected to offset some of the financial and strategic pressures from that disappointment.